These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 3551154

  • 1. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)--a preliminary report on a placebo-controlled double-blind study.
    Diehm C, Stammler F, Hübsch-Müller C, Eckstein HH, Simini B.
    Vasa Suppl; 1987; 17():52-6. PubMed ID: 3551154
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical experiences with prostaglandin E1 in severe peripheral artery disease].
    Carlson LA, Jogestrand T, Kaijser L, Olsson AG.
    Lakartidningen; 1977 Aug 03; 74(31):2629-33. PubMed ID: 895269
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of peripheral arterial occlusive disease in stage IIb with intermittent short-term infusion of prostaglandin E1.
    Zanke BW, Hach W, Ozen Y, Sauerwein G.
    Vasa Suppl; 1987 Aug 03; 17():36-8. PubMed ID: 3470964
    [No Abstract] [Full Text] [Related]

  • 4. Prostaglandin E1 in chronic arterial disease--a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Vasa Suppl; 1987 Aug 03; 17():39-43. PubMed ID: 3470965
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
    Trifiletti A, Scamardi R, Pizzoleo MA, Sottilotta G, Soraci S, Attinà A, Bagnato L, Barbera N.
    Panminerva Med; 1999 Mar 03; 41(1):15-7. PubMed ID: 10230250
    [Abstract] [Full Text] [Related]

  • 8. [1st experiences with prostaglandin E1 long-term intra-arterial perfusion in advanced arterial occlusive disease of the lower extremities stage IV].
    Gruss JD, Kawai S, Karadedos C, Bartels D.
    Dtsch Med Wochenschr; 1978 Oct 13; 103(41):1624-5. PubMed ID: 699778
    [No Abstract] [Full Text] [Related]

  • 9. [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].
    Heidrich H, Lammersen T.
    Dtsch Med Wochenschr; 1985 Aug 23; 110(34):1283-5. PubMed ID: 4040847
    [Abstract] [Full Text] [Related]

  • 10. [Prostaglandin E1 in decreased arterial perfusion].
    Pilger E, Bertuch H, Stark G, Hönigl K.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):490-5. PubMed ID: 3062908
    [Abstract] [Full Text] [Related]

  • 11. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 Jul 15; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

  • 12. Clinical application of prostaglandin E1 in cases of occlusive arterial disease.
    Mishima Y.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Jul 15; 15():547-8. PubMed ID: 2936166
    [Abstract] [Full Text] [Related]

  • 13. Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE1 and nucleotide phosphates in patients with peripheral arterial occlusive disease.
    Caspary L, Creutzig A, Alexander K.
    Vasa Suppl; 1987 Jul 15; 17():17-22. PubMed ID: 3470960
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial.
    Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke J.
    J Vasc Surg; 1984 Jan 15; 1(1):160-70. PubMed ID: 6384558
    [Abstract] [Full Text] [Related]

  • 15. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A, Serricchio M, Tondi P, Nolfe G.
    Drugs Exp Clin Res; 1999 Jan 15; 25(1):29-36. PubMed ID: 10337502
    [Abstract] [Full Text] [Related]

  • 16. [Controlled study with nicergoline and placebo in cerebral and peripheral vascular insufficiency in the aged].
    Cascone A, Liverta C, Pollini C.
    Minerva Cardioangiol; 1978 Jan 15; 26(1-2):95-100. PubMed ID: 347330
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of benfurodil hemiscucinate (Eucilat) on various hemorheologic parameters in patients with chronic peripheral obstructive arteriopathies].
    Mozzi E, Annoni F, Chiurazzi D, Rossi R, Pacini F, Martini A.
    Minerva Cardioangiol; 1984 Mar 15; 32(3):141-9. PubMed ID: 6374499
    [No Abstract] [Full Text] [Related]

  • 18. Prostaglandin E1 in chronic arterial disease: a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Prog Clin Biol Res; 1987 Mar 15; 242():445-51. PubMed ID: 3313418
    [No Abstract] [Full Text] [Related]

  • 19. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency.
    Bauer U.
    Arzneimittelforschung; 1984 Mar 15; 34(6):716-20. PubMed ID: 6386008
    [Abstract] [Full Text] [Related]

  • 20. Intra-arterial perfusion with prostaglandin E1 in patients with intermittent claudication.
    Rudofsky G, Altenhoff B, Meyer P, Lohmann A.
    Vasa Suppl; 1987 Mar 15; 17():47-51. PubMed ID: 3551153
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.